Bimekizumab safe and effective for treatment of moderate-to-severe hidradenitis suppurative
1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse ...
Tag: IL-17A
Sonelokimab 120 mg or less showed significant clinical benefit over placebo in patients with plaque psoriasis
1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in ...